Status
Conditions
Treatments
About
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer [18F]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study by our group examining the effects of tDCS on treatment adherence in schizophrenia (REB #103-2018).
Full description
The aim of our study is to examine if tDCS induces synaptic density changes in patients with schizophrenia using [18F]SDM-8. Our study will help elucidate the mechanism through which tDCS affects the brain.
PET scans will be offered to participants that meet the inclusion and exclusion criteria at the initial screening visit. Participants will be scanned with the novel PET tracer [18F]SDM-8 to quantify synaptic density levels. PET scans will be timed to coincide to the two time-points, before and after 2-weeks of tDCS treatment that is completed under the parent study protocol (REB #103-2018). Clinical assessments will be done at the same time.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are:
Exclusion criteria
The exclusion criteria for this study will be the same as the parent study (REB 103-2018). The parent study exclusion criteria are:
Additional exclusion criteria for this companion study are:
20 participants in 1 patient group
Loading...
Central trial contact
Philip Gerretsen, MD, PhD; Ariel Graff, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal